keyword
MENU ▼
Read by QxMD icon Read
search

Histological subtypes oral cancer

keyword
https://www.readbyqxmd.com/read/28607808/concomitant-chemoradiotherapy-associated-oral-lesions-in-patients-with-oral-squamous-cell-carcinoma
#1
Sadia Minhas, Muhammad Kashif, Wasif Altaf, Nadeem Afzal, Abdul Hanan Nagi
OBJECTIVE: : Oral squamous-cell carcinoma (OSCC) accounts for >90% of oral cancers affecting adults mostly between the fourth to seventh decades of life. The most common OSCC treatment is concomitant chemoradiotherapy (CCRT) having both loco-regional and distant control, but CCRT has acute and chronic toxic effects on adjacent normal tissue. This study aimed to determine the side effects of CCRT on the oral mucosa and to characterize the clinicopathology of oral lesions in patients with OSCC...
May 2017: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28487883/genetic-and-epigenetic-profiling-of-a-solitary-peutz-jeghers-colon-polyp
#2
Heinz Linhart, Felix Bormann, Barbara Hutter, Benedikt Brors, Frank Lyko
Colon polyps represent precursor lesions of colon cancers and their malignant potential varies according to histological subtype. A rare subtype of colon polyps is the Peutz-Jeghers (PJ) polyp. PJ polyps mostly occur in the context of Peutz-Jeghers syndrome, which is characterized by the development of multiple polyps in the intestinal tract and hyperpigmentation of oral mucosa and lips. Peutz-Jeghers is an autosomal dominant disorder caused by pathogenic variants of the serine threonine kinase STK11. PJ polyps very rarely occur outside of the syndrome and are then referred to as solitary PJ polyps...
May 2017: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/28468797/selective-inhibition-of-nuclear-export-with-selinexor-in-patients-with-non-hodgkin-s-lymphoma
#3
John Kuruvilla, Michael Savona, Rachid Baz, Morten Mau-Sorensen, Nashat Gabrail, Ramiro Garzon, Richard Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian Flinn, Meagan Jacoby, T J Unger, Jean R Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez
Patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B cell lymphoma (DLBCL), Richter's transformation, mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) were enrolled...
May 3, 2017: Blood
https://www.readbyqxmd.com/read/28293802/history-of-hypertension-heart-disease-and-diabetes-and-ovarian-cancer-patient-survival-evidence-from-the-ovarian-cancer-association-consortium
#4
Albina N Minlikeeva, Jo L Freudenheim, Rikki A Cannioto, J Brian Szender, Kevin H Eng, Francesmary Modugno, Roberta B Ness, Michael J LaMonte, Grace Friel, Brahm H Segal, Kunle Odunsi, Paul Mayor, Emese Zsiros, Barbara Schmalfeldt, Rüdiger Klapdor, Thilo Dӧrk, Peter Hillemanns, Linda E Kelemen, Martin Kӧbel, Helen Steed, Anna de Fazio, Susan J Jordan, Christina M Nagle, Harvey A Risch, Mary Anne Rossing, Jennifer A Doherty, Marc T Goodman, Robert Edwards, Keitaro Matsuo, Mika Mizuno, Beth Y Karlan, Susanne K Kjær, Estrid Høgdall, Allan Jensen, Joellen M Schildkraut, Kathryn L Terry, Daniel W Cramer, Elisa V Bandera, Lisa E Paddock, Lambertus A Kiemeney, Leon F Massuger, Jolanta Kupryjanczyk, Andrew Berchuck, Jenny Chang-Claude, Brenda Diergaarde, Penelope M Webb, Kirsten B Moysich
PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype. METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma...
May 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28259610/vandetanib-plus-gemcitabine-versus-placebo-plus-gemcitabine-in-locally-advanced-or-metastatic-pancreatic-carcinoma-vip-a-prospective-randomised-double-blind-multicentre-phase-2-trial
#5
RANDOMIZED CONTROLLED TRIAL
Gary Middleton, Daniel H Palmer, William Greenhalf, Paula Ghaneh, Richard Jackson, Trevor Cox, Anthony Evans, Victoria E Shaw, Jonathan Wadsley, Juan W Valle, David Propper, Harpreet Wasan, Stephen Falk, David Cunningham, Fareeda Coxon, Paul Ross, Srinivasan Madhusudan, Nick Wadd, Pippa Corrie, Tamas Hickish, Eithne Costello, Fiona Campbell, Charlotte Rawcliffe, John P Neoptolemos
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer...
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28182134/differential-pharmacology-and-clinical-utility-of-sonidegib-in-advanced-basal-cell-carcinoma
#6
REVIEW
Mohd Wahid, Arshad Jawed, Sajad Ahmad Dar, Raju K Mandal, Shafiul Haque
Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent tumors and can treat locally advanced BCC patients who are not candidates for surgery or radiation therapy. The BOLT clinical trials were conducted to evaluate the efficacy/potency of sonidegib in the treatment of advanced BCC or metastatic BCC. The patients were randomized in 1:2 ratios to receive 200 or 800 mg oral sonidegib daily, stratified by disease, histological subtype and geographical region...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27746875/angiosarcoma-a-case-report-of-gingival-disease-with-both-palatine-tonsils-localization
#7
Frédéric Chamberland, Tristan Maurina, Séverine Degano-Valmary, Thierry Spicarolen, Loïc Chaigneau
Angiosarcomas are one of the rarest subtypes of sarcomas; those are malignant vascular tumors arising from vascular endothelial cells. Occurrence of intra-oral angiosarcoma is extremely rare (0.0077% of all cancers in Europe). We present here, to our knowledge, the first case of a 83-year-old man with gingival and both palatine tonsils localization of a grade-two angiosarcoma discovered after a two months history of a painful lesion followed by hematoma and spontaneous bleeding. Chemotherapy with paclitaxel and hemostatic radiotherapy were inefficient and he died seven months after the first symptoms...
September 5, 2016: Rare Tumors
https://www.readbyqxmd.com/read/27472701/concomitant-etoposide-and-cisplatin-provided-improved-survival-compared-with-docetaxel-and-cisplatin-in-patients-with-locally-advanced-non-small-cell-lung-cancer-treated-with-chemoradiotherapy
#8
Fatma Sen, Makbule Tambas, Kubra Ozkaya, Murat Emin Guveli, Rumeysa Ciftci, Berker Ozkan, Ethem Nezih Oral, Esra Kaytan Saglam, Pinar Saip, Alper Toker, Adalet Demir, Pinar Firat, Adnan Aydiner, Yesim Eralp
Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.Patients treated with either EP or DP and concurrent radiotherapy from 2004 to2012 were identified and their detailed medical records and follow-up information were obtained for analysis in this retrospective study...
July 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27334838/t-lak-cell-originated-protein-kinase-topk-as-a-prognostic-factor-and-a-potential-therapeutic-target-in-ovarian-cancer
#9
Yuji Ikeda, Jae-Hyun Park, Takashi Miyamoto, Naofumi Takamatsu, Taigo Kato, Akiko Iwasa, Shuhei Okabe, Yuichi Imai, Keiichi Fujiwara, Yusuke Nakamura, Kosei Hasegawa
BACKGROUND: We aimed to clarify the clinical significance of TOPK (T-lymphokine-activated killer cell-originated protein kinase) expression in ovarian cancer and evaluate the possible effect of TOPK inhibitors, OTS514 and OTS964, on ovarian cancer cells. METHODS: TOPK expression was examined by immunohistochemistry using 163 samples with epithelial ovarian cancer (EOC). TOPK protein level and FOXM1 transcriptional level in ovarian cancer cell lines were examined by Western blot and RT-PCR, respectively...
December 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27325851/ovarian-cancer-risk-factors-by-histologic-subtype-an-analysis-from-the-ovarian-cancer-cohort-consortium
#10
Nicolas Wentzensen, Elizabeth M Poole, Britton Trabert, Emily White, Alan A Arslan, Alpa V Patel, V Wendy Setiawan, Kala Visvanathan, Elisabete Weiderpass, Hans-Olov Adami, Amanda Black, Leslie Bernstein, Louise A Brinton, Julie Buring, Lesley M Butler, Saioa Chamosa, Tess V Clendenen, Laure Dossus, Renee Fortner, Susan M Gapstur, Mia M Gaudet, Inger T Gram, Patricia Hartge, Judith Hoffman-Bolton, Annika Idahl, Michael Jones, Rudolf Kaaks, Victoria Kirsh, Woon-Puay Koh, James V Lacey, I-Min Lee, Eva Lundin, Melissa A Merritt, N Charlotte Onland-Moret, Ulrike Peters, Jenny N Poynter, Sabina Rinaldi, Kim Robien, Thomas Rohan, Dale P Sandler, Catherine Schairer, Leo J Schouten, Louise K Sjöholm, Sabina Sieri, Anthony Swerdlow, Anna Tjonneland, Ruth Travis, Antonia Trichopoulou, Piet A van den Brandt, Lynne Wilkens, Alicja Wolk, Hannah P Yang, Anne Zeleniuch-Jacquotte, Shelley S Tworoger
PURPOSE: An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3). PATIENTS AND METHODS: Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other)...
August 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27230992/mage-a1-6-%C3%A2-expression-in-patients-with-head-and-neck-squamous-cell-carcinoma-impact-on-clinical-patterns-and-oncologic-outcomes
#11
Sang Tae Noh, Hyoung Shin Lee, Soo Jin Lim, Sung Won Kim, Hee Kyung Chang, Junghwan Oh, Chang-Ho Jeon, Jong Wook Park, Kang Dae Lee
BACKGROUND: Various subtypes of melanoma-associated antigens (MAGEs) are expressed in the tumor tissues of patients with head and neck squamous cell carcinoma (HNSCC). However, little data are currently available on how the gene expression of MAGEs impacts clinical patterns and oncologic outcomes. We have therefore evaluated the expression of MAGE-A1-6 (A1-6) subtypes in tumor tissues of patients with HNSCC and the clinical impact of this expression. METHODS: This was a retrospective review of 53 patients with histologically proven HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx who underwent both treatment and analysis by reverse transcription (RT)-PCR assay with a common primer to identify the expression of MAGE-A1-6 subtypes in the tumor tissue...
October 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26960462/factors-predicting-lapatinib-efficacy-in-her-2-metastatic-breast-carcinoma-does-it-work-better-in-different-histologic-subtypes
#12
S S Göksu, H Bozcuk, L Koral, B Çakar, S Gündüz, A M Tatlı, D Arslan, M Uysal, M Koçer, M Artaç, B Karabulut, H S Coşkun, M Özdoğan, B Savaş
CONTEXT: Introduction of trastuzumab, a recombinant monoclonal antibody against the extracellular domain of HER-2, is a cornerstone in the treatment of HER-2+ breast carcinoma. However, many cancers that have an initial response to trastuzumab will progress some time later. After progression on trastuzumab-based first-line treatment, there are several options. Although TDM-1 (Trastuzumab emtansine) has prolonged progression-free survival (PFS) and overall survival in patients previously treated with trastuzumab and taxane, it is still not available in Turkey...
October 2015: Indian Journal of Cancer
https://www.readbyqxmd.com/read/26838208/p53-expression-helps-identify-high-risk-oral-tongue-pre-malignant-lesions-and-correlates-with-patterns-of-invasive-tumour-front-and-tumour-depth-in-oral-tongue-squamous-cell-carcinoma-cases
#13
Thangaraj Soundara Viveka, Vidyarani Shyamsundar, Arvind Krishnamurthy, Pratibha Ramani, Vijayalakshmi Ramshankar
Oral tongue squamous cell carcinoma (OTSCC) is the most common oral cancer subtype with a maximum propensity for regional spread. Our objective was to study if p53 expression might have any correlation with aggressive patterns of invasion within oral tongue cancers as well as with the histologically identified degree of oral tongue dysplasia. p53 immunoexpression was studied using immunohistochemistry in early staged OTSCCs (n=155), oral tongue dysplasias, (n=29) and oral tongue normal specimens (n=10) and evaluated for correlations with histological and clinicopathological parameters...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/26833519/non-melanoma-skin-cancer
#14
Liezel L Griffin, Faisal Rehman Ali, John T Lear
Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common...
February 2016: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/26794930/everolimus-versus-sunitinib-for-patients-with-metastatic-non-clear-cell-renal-cell-carcinoma-aspen-a-multicentre-open-label-randomised-phase-2-trial
#15
RANDOMIZED CONTROLLED TRIAL
Andrew J Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M Stadler, Robert J Jones, Jorge A Garcia, Ulka N Vaishampayan, Joel Picus, Robert E Hawkins, John D Hainsworth, Christian K Kollmannsberger, Theodore F Logan, Igor Puzanov, Lisa M Pickering, Christopher W Ryan, Andrew Protheroe, Christine M Lusk, Sadie Oberg, Daniel J George
BACKGROUND: Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF receptor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma. METHODS: We enrolled patients with metastatic papillary, chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previous systemic treatment...
March 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26668515/possible-association-between-hepatitis-c-virus-and-malignancies-different-from-hepatocellular-carcinoma-a-systematic-review
#16
REVIEW
Sirio Fiorino, Letizia Bacchi-Reggiani, Dario de Biase, Adele Fornelli, Michele Masetti, Andrea Tura, Fabio Grizzi, Matteo Zanello, Laura Mastrangelo, Raffaele Lombardi, Giorgia Acquaviva, Luca di Tommaso, Arrigo Bondi, Michela Visani, Sergio Sabbatani, Laura Pontoriero, Carlo Fabbri, Andrea Cuppini, Annalisa Pession, Elio Jovine
AIM: To summarize the current knowledge about the potential relationship between hepatitis C virus (HCV) infection and the risk of several extra-liver cancers. METHODS: We performed a systematic review of the literature, according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) Statement. We extracted the pertinent articles, published in MEDLINE and the Cochrane Library, using the following search terms: neoplasm/cancer/malignancy/tumor/carcinoma/adeno-carcinoma and non-Hodgkin lymphomas, kidney/renal-, cholangio-, pancreatic-, thyroid-, breast-,oral-, skin-, prostate-, lung-, colon-, stomach-, haematologic...
December 7, 2015: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/26668446/molecular-concept-in-human-oral-cancer
#17
REVIEW
Akhilesh Krishna, Shraddha Singh, Vijay Kumar, U S Pal
The incidence of oral cancer remains high in both Asian and Western countries. Several risk factors associated with development of oral cancer are now well-known, including tobacco chewing, smoking, and alcohol consumption. Cancerous risk factors may cause many genetic events through chromosomal alteration or mutations in genetic material and lead to progression and development of oral cancer through histological progress, carcinogenesis. Oral squamous carcinogenesis is a multistep process in which multiple genetic events occur that alter the normal functions of proto-oncogenes/oncogenes and tumor suppressor genes...
January 2015: National Journal of Maxillofacial Surgery
https://www.readbyqxmd.com/read/26632951/five-and-10-year-cause-specific-survival-rates-in-carcinoma-of-the-minor-salivary-gland
#18
H Michael Baddour, Stacey A Fedewa, Amy Y Chen
IMPORTANCE: Previous studies of prognostic factors of carcinoma of the minor salivary gland (MSG) have been limited to single-institution studies and small case series. Thus, limited data are available to guide the head and neck oncologist in counseling patients on the prognosis and management of these malignant neoplasms. OBJECTIVE: To examine 5- and 10-year cause-specific survival (CSS) rates of MSG carcinomas across all histologic subtypes and head and neck tumor subsites...
January 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/26514182/antitumor-activity-of-the-multikinase-inhibitor-regorafenib-in-patient-derived-xenograft-models-of-gastric-cancer
#19
Hung Huynh, Richard Ong, Dieter Zopf
BACKGROUND: Unresectable gastric cancer is associated with poor outcomes, with few treatment options available after failure of cytotoxic chemotherapy. Clinical trials of targeted therapies have generally shown no survival benefit in gastric cancer, with the exceptions of the antibodies ramucirumab (anti-VEGFR2) and trastuzumab (anti-HER2/neu). Given the efficacy of the multikinase inhibitor regorafenib in other gastrointestinal tumors, we investigated its potential in gastric cancer...
2015: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/26381550/cancer-incidence-among-minnesota-taconite-mining-industry-workers
#20
Elizabeth M Allen, Bruce H Alexander, Richard F MacLehose, Heather H Nelson, Gurumurthy Ramachandran, Jeffrey H Mandel
PURPOSE: To evaluate cancer incidence among Minnesota taconite mining workers. METHODS: We evaluated cancer incidence between 1988 and 2010 in a cohort of 40,720 Minnesota taconite mining workers used between 1937 and 1983. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated by comparing numbers of incident cancers with frequencies in the Minnesota Cancer Surveillance System. SIRs for lung cancer by histologic subtypes were also estimated...
November 2015: Annals of Epidemiology
keyword
keyword
96103
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"